---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-017807"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:11:34.065058+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut

## Summary
- Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
- Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.
- Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).
- Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.
- FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58).

## SEC filing metadata
- accession: 0001140361-24-017807
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/ef20026031_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-017807
- JSON: https://secwatch.observer/filing/0001140361-24-017807.json
- Plain text: https://secwatch.observer/filing/0001140361-24-017807.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.
  - Period: the fiscal third quarter ended February 29, 2024
  - Result: reported results
  source text: On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.